David Gilligan
Overview
Explore the profile of David Gilligan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
748
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Middleton G, Robbins H, Fletcher P, Savage J, Mehmi M, Summers Y, et al.
NPJ Precis Oncol
. 2025 Mar;
9(1):67.
PMID: 40069402
There are no current stratified medicine options for STK11-deficient NSCLC. STK11 loss mediates mTORC activation, GLUT1 up-regulation and increased glycolysis. This metabolic reprogramming might represent a therapeutic vulnerability targetable with...
2.
Brady N, OConnell S, Gilligan D, Madden C, Gannon L, Howson V, et al.
J Adv Nurs
. 2025 Jan;
PMID: 39844513
Introduction: Job satisfaction and intention to leave have been consistently linked to the working environment. However, there are few studies of interventions for improving the environment or staff outcomes. Aim:...
3.
Szlosarek P, Creelan B, Sarkodie T, Nolan L, Taylor P, Olevsky O, et al.
JAMA Oncol
. 2024 Feb;
10(4):475-483.
PMID: 38358753
Importance: Arginine deprivation using ADI-PEG20 (pegargiminase) combined with chemotherapy is untested in a randomized study among patients with cancer. ATOMIC-Meso (ADI-PEG20 Targeting of Malignancies Induces Cytotoxicity-Mesothelioma) is a pivotal trial...
4.
Homicsko K, Zygoura P, Norkin M, Tissot S, Shakarishvili N, Popat S, et al.
J Immunother Cancer
. 2023 Oct;
11(10).
PMID: 37880184
Background: Few tissue biomarkers exist to date that could enrich patient with cancer populations to benefit from immune checkpoint blockade by programmed cell death protein 1/ligand-1 (PD-/L-1) inhibitors. PD-L1 expression...
5.
Robinson S, Gault A, Kathirgamakarthigeyan S, Gilligan D
Radiother Oncol
. 2023 Oct;
189:109940.
PMID: 37813311
Significant variation in treatment centre setup and radiotherapy practice for thymic epithelial tumours (TET) was identified through a comprehensive survey of current UK Clinical (Radiation) Oncology practice. Multi-centre collaboration and...
6.
Hayat R, Ahmed S, Badiger R, Lee S, Peryt A, Gilligan D, et al.
Oxf Med Case Reports
. 2023 Jun;
2023(5):omac151.
PMID: 37260730
This case report explores a 34-year-old male diagnosed with mesothelioma who had no known risk factors. The patient initially was treated for empyema with antibiotics but later represented to hospital...
7.
Banna G, Addeo A, Zygoura P, Tsourti Z, Popat S, Curioni-Fontecedro A, et al.
Lung Cancer
. 2022 Jun;
169:77-83.
PMID: 35660972
Introduction: Clinical and laboratory parameters associated with response for patients with advanced pre-treated malignant pleural mesothelioma (MPM) are lacking. We aimed to identify prognostic and predictive markers among patients with...
8.
Kieran R, de Paula B, Hubank M, Barker A, Paterson A, Gilligan D, et al.
JCO Precis Oncol
. 2022 Jan;
5:1579-1583.
PMID: 34994644
No abstract available.
9.
Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, et al.
Nature
. 2020 Sep;
585(7826):E21.
PMID: 32887973
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
10.
Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, et al.
Nature
. 2020 Jul;
583(7818):807-812.
PMID: 32669708
The majority of targeted therapies for non-small-cell lung cancer (NSCLC) are directed against oncogenic drivers that are more prevalent in patients with light exposure to tobacco smoke. As this group...